Compare VNCE & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VNCE | CNTB |
|---|---|---|
| Founded | 2002 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 138.5M | 140.4M |
| IPO Year | 2013 | 2020 |
| Metric | VNCE | CNTB |
|---|---|---|
| Price | $10.67 | $0.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $15.00 | $5.88 |
| AVG Volume (30 Days) | 326.0K | ★ 1.3M |
| Earning Date | 12-08-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 132.45 | N/A |
| EPS | ★ 0.65 | N/A |
| Revenue | ★ $300,007,000.00 | $64,000.00 |
| Revenue This Year | $12.72 | $11,287.85 |
| Revenue Next Year | $17.67 | $74.11 |
| P/E Ratio | $16.09 | ★ N/A |
| Revenue Growth | ★ 2.23 | N/A |
| 52 Week Low | $1.95 | $0.73 |
| 52 Week High | $13.78 | $3.82 |
| Indicator | VNCE | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 45.67 | 37.76 |
| Support Level | $9.82 | $0.73 |
| Resistance Level | $13.41 | $2.62 |
| Average True Range (ATR) | 1.05 | 0.06 |
| MACD | -0.33 | 0.03 |
| Stochastic Oscillator | 10.64 | 33.63 |
Vince Holding Corp is a fashion brand that is engaged in wholesale and retail delivery of luxury essentials like women's and men's apparel, women's and men's footwear, and handbags. Its offers women's collections of luxurious cashmere sweaters and silk blouses, leather and suede leggings and jackets, dresses, denim, pants, tanks and t-shirts, and a growing assortment of outerwear. It focuses on developing an elevated collection of Vince apparel and accessories to serve the luxurious need of the customer. The company manages its business in three segments namely Vince Wholesale and Vince Direct-to-consumer. It operates its e-commerce business through its website. Maximum of its revenue generated from Vince Wholesale segment.
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.